PlainPharmaWatch

CMS Open Payments · Tool

ZOLL Respicardia, Inc. vs Carl Zeiss Meditec USA, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

ZOLL Respicardia, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 435, versus 348 for the other company. Its single largest recorded recipient represents 0.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

ZOLL Respicardia, Inc.
HHI 435 · top recipient 0.2%
Ranked #1,344 of 1,838 companies by HHI
Carl Zeiss Meditec USA, Inc.
HHI 348 · top recipient 0.2%
Ranked #1,422 of 1,838 companies by HHI

Payment Overview

Total Payments
$718.3K
% of Industry
0.0%
Transactions
1,762
Avg per Transaction
$407.69
Recipients
1,630
Avg per Recipient
$440.70
Payment Types
4
Top Payment Type
Consulting Fee
Total Payments
$719.3K
% of Industry
0.0%
Transactions
2,435
Avg per Transaction
$295.39
Recipients
2,435
Avg per Recipient
$295.39
Payment Types
7
Top Payment Type
Consulting Fee

Highlighted values indicate the higher figure for each metric.

Total payments compared

ZOLL Respicardia, Inc. vs Carl Zeiss Meditec USA, Inc. - total reported payments in CMS Open Payments PY2024

Carl Zeiss Meditec USA, Inc.$719.3KZOLL Respicardia, Inc.$718.3K

Payment Types Breakdown

ZOLL Respicardia, Inc.

Consulting Fee $148.6K

20.7%

Food and Beverage $89.9K

12.5%

Travel and Lodging $56.5K

7.9%

Compensation for Faculty or Speaker (Medical Education) $30.9K

4.3%

Carl Zeiss Meditec USA, Inc.

Consulting Fee $297.9K

41.4%

Food and Beverage $134.4K

18.7%

Travel and Lodging $97.2K

13.5%

Compensation for Services Other Than Consulting $83.7K

11.6%

Long-Term Medical Supply or Device Loan $74.7K

10.4%

Debt Forgiveness $23.4K

3.3%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

ZOLL Respicardia, Inc.

  1. 1

    WILLIAM ABRAHAM

    $51,850.00 · 9 txns

  2. 2

    ATUL MALHOTRA

    $29,169.55 · 5 txns

  3. 3

    SHAHROKH JAVAHERI

    $16,550.46 · 14 txns

  4. 4

    SAMER AL-KHUDARI

    $11,684.15 · 13 txns

  5. 5

    Alan Schwartz

    $9,081.38 · 5 txns

Carl Zeiss Meditec USA, Inc.

  1. 1

    JON GORDON DISHLER

    $120,000.00 · 2 txns

  2. 2

    Adventhealth Orlando

    $21,985.41 · 1 txns

  3. 3

    Largo Medical Center

    $21,648.49 · 2 txns

  4. 4

    OMAR RAZZAQUE SHAKIR

    $17,223.03 · 18 txns

  5. 5

    JORGE A FORTUN

    $12,766.12 · 8 txns

Summary Comparison

Metric ZOLL Respicardia, Inc. Carl Zeiss Meditec USA, Inc.
Total Payments $718.3K $719.3K
% of Industry Total 0.0% 0.0%
Transaction Count 1,762 2,435
Avg per Transaction $407.69 $295.39
Recipient Count 1,630 2,435
Avg per Recipient $440.70 $295.39
Payment Type Count 4 7
Top Payment Type Consulting Fee Consulting Fee

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.